Special Issue

Genome Maintenance and Cancer Predisposition

Message from the Guest Editor

Eukaryotic organisms have developed a variety of genome maintenance mechanisms to preserve their genetic information. Failure in these mechanisms can results in genomic instability, a hallmark of cancer. Mutations in genome maintenance genes have been reported to cause cancer predisposition syndromes. Patients with these syndromes display elevated levels of DNA damage and chromosome alterations that lead to genomic instability. At the same time, elevated DNA damage and genomic instability in cancer cells may lead to upregulation of residual DNA repair pathways, which support tumor cell survival. This in turn contributes to therapeutic resistance, particularly for DNA-damaging chemotherapy, leading to the progression of malignancy. We welcome reviews, new methods, and original articles covering many aspects of genome maintenance and cancer predisposition. These include but are not limited to cell cycle checkpoints, mitosis, DNA damage response, DNA replication, DNA repair, chromatin regulation, and chromosome segregation, many of which are dysregulated during cancer progression.

Guest Editor

Dr. Eishi Noguchi

Department of Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, PA 19102, USA

Deadline for manuscript submissions

closed (15 July 2022)

GCAT
TACG
GCAT

Genes

an Open Access Journal by MDPI

Impact Factor 3.1
CiteScore 5.9
Indexed in PubMed

mdpi.com/si/74241

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

mdpi.com/journal/genes

MDPI

GCAT
TACG
GCAT

Genes

an Open Access Journal by MDPI

Impact Factor 3.1
CiteScore 5.9
Indexed in PubMed

mdpi.com/journal/genes

MDPI

About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))